Novo Nordisk shares recover as FDA pledges to crack down on illegal weight-loss drug copies

The U.S. Food and Drug Administration has pledged to take swift action against companies mass-marketing unapproved copycat drugs, stating that it cannot verify the quality, safety, or effectiveness of these products. This announcement, made on February 6, 2026, follows the launch of a significantly cheaper compounded version of Wegovy by Hims & Hers Health, Inc. HIMS. The regulatory move has provided immediate support to Novo Nordisk A/S NVO, the manufacturer of the FDA-approved weight-loss medicine, which has its headquarters in Denmark DK and operates extensively in the United States US.